Australia's most trusted
source of pharma news
Saturday, 15 March 2025
Posted 13 March 2025 PM
Roche has shored up its obesity portfolio by partnering with Zealand Pharma for a much-hyped amylin analog in Phase 2 trials in a deal worth up to AU$8.3 billion.
Zealand announced last August that it was looking for a partner for petrelintide, which has a different mechanism of action than the GLP-1 RAs dominating the market. The pharma said it has weight loss results similar to GLP-1 RAs but with a better tolerability profile.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.